keyword
MENU ▼
Read by QxMD icon Read
search

Lurasidone

keyword
https://www.readbyqxmd.com/read/28539103/possible-oxcarbazepine-inductive-effects-on-aripiprazole-metabolism-a-case-report
#1
Ian R McGrane, Joshua G Loveland, Jose de Leon
Oxcarbazepine is a cytochrome P450 (CYP) 3A4 inducer, which is structurally similar to carbamazepine. Although lacking Food and Drug Administration approval, oxcarbazepine is sometimes prescribed to treat aggressive behavior in youth with autism spectrum disorder (ASD). These youths may also be taking second-generation antipsychotics, some of which are substrates of the CYP3A4 metabolic pathway. The combination of these medications may result in decreased serum antipsychotic concentrations, potentially reducing effectiveness...
January 1, 2017: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/28499900/lurasidone-in-post-menopausal-females-with-major-depressive-disorder-with-mixed-features-post-hoc-analysis-of-a-placebo-controlled-trial
#2
John Sramek, Anthony Loebel, Michael Murphy, Yongcai Mao, Andrei Pikalov, Neal R Cutler
BACKGROUND: Several studies have found that depressed, post-menopausal females may respond differently to antidepressants compared to pre-menopausal females. The atypical antipsychotic lurasidone, whose mechanism of action differs from SSRIs and other standard antidepressants, was shown in a 6-week randomized, flexible-dose, placebo-controlled study (n=209), to be effective in treating major depressive disorder (MDD) with mixed features (subthreshold hypomanic symptoms). This post-hoc analysis assessed the efficacy of lurasidone in this study by menopausal status...
May 9, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28490709/-research-progress-in-mechanisms-and-clinical-application-for-blonanserin-and-lurasidone-in-improving-cognitive-function-of-schizophrenia
#3
Qi Zheng, Bangshan Liu, Shuyin Xu, Mei Liao, Yan Zhang, Lingjiang Li
Cognition deficit is one of the most common symptoms of schizophrenia, including abstract thinking and memory, and attention deficits. Previous studies have suggested that the improvement of cognition is very important for the recovery of disease and social function for the patients. Recent studies indicated that two new atypical antipsychotics, blonanserin and lurasidone, are expected to improve the cognitive impairment in patients with schizophrenia. This review introduces pathogenesis of cognitive impairment in schizophrenia, mechanisms of blonanserin and lurasidone in the improvement of cognitive impairment and progress in their clinical application for schizophrenia...
April 28, 2017: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://www.readbyqxmd.com/read/28478684/lurasidone-associated-neutropenia
#4
Sarvesh Singh, Hafeez Ahmad, Alexander Panickacheril John
No abstract text is available yet for this article.
May 1, 2017: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/28475373/efficacy-and-safety-of-lurasidone-in-adolescents-with-schizophrenia-a-6-week-randomized-placebo-controlled-study
#5
Robert Goldman, Antony Loebel, Josephine Cucchiaro, Ling Deng, Robert L Findling
OBJECTIVE: To evaluate the efficacy and safety of lurasidone in acutely symptomatic adolescent patients with schizophrenia. METHODS: Patients aged 13-17 years were randomly assigned to 6 weeks of double-blind, fixed-dose lurasidone (40 or 80 mg/day) or placebo. Primary and key secondary efficacy measures were change from baseline to week 6 in the Positive and Negative Symptom Scale (PANSS) total score and Clinical Global Impressions-Severity (CGI-S) score, respectively, using mixed model for repeated measurement (MMRM) analysis...
May 5, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28463099/remission-and-recovery-associated-with-lurasidone-in-the-treatment-of-major-depressive-disorder-with-subthreshold-hypomanic-symptoms-mixed-features-post-hoc-analysis-of-a-randomized-placebo-controlled-study-with-longer-term-extension-corrigendum
#6
Joseph F Goldberg, Daisy Ng-Mak, Cynthia Siu, Chien-Chia Chuang, Krithika Rajagopalan, Antony Loebel
No abstract text is available yet for this article.
May 2, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28455126/neurochemical-arguments-for-the-use-of-dopamine-d4-receptor-stimulation-to-improve-cognitive-impairment-associated-with-schizophrenia
#7
Mei Huang, Sunoh Kwon, Wenqi He, Herbert Y Meltzer
BACKGROUND: Dopamine (DA) D4 receptors have been implicated in schizophrenia and the ability of some atypical antipsychotic drugs (APDs) to improve the cognitive impairment associated with schizophrenia (CIAS). Systemic administration of a D4 agonist, PD168077, at a sub-effective dose, together with a sub-effective dose of lurasidone, an atypical APD which is a weak D4 receptor antagonist, reversed the deficit in novel object recognition (NOR) in rats treated subchronically with phencyclidine (PCP), a rodent model of CIAS...
April 25, 2017: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/28431800/genetic-predictors-of-antipsychotic-response-to-lurasidone-identified-in-a-genome-wide-association-study-and-by-schizophrenia-risk-genes
#8
Jiang Li, Akane Yoshikawa, Mark D Brennan, Timothy L Ramsey, Herbert Y Meltzer
Biomarkers which predict response to atypical antipsychotic drugs (AAPDs) increases their benefit/risk ratio. We sought to identify common variants in genes which predict response to lurasidone, an AAPD, by associating genome-wide association study (GWAS) data and changes (Δ) in Positive And Negative Syndrome Scale (PANSS) scores from two 6-week randomized, placebo-controlled trials of lurasidone in schizophrenia (SCZ) patients. We also included SCZ risk SNPs identified by the Psychiatric Genomics Consortium using a polygenic risk analysis...
April 18, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28357969/lurasidone-for-major-depressive-disorder-with-mixed-features-and-anxiety-a-post-hoc-analysis-of-a-randomized-placebo-controlled-study
#9
Joyce Tsai, Michael E Thase, Yongcai Mao, Daisy Ng-Mak, Andrei Pikalov, Antony Loebel
OBJECTIVE: The aim of this post-hoc analysis was to evaluate the efficacy of lurasidone in treating patients with major depressive disorder (MDD) with mixed features who present with mild and moderate-to-severe levels of anxiety. METHODS: The data in this analysis were derived from a study of patients meeting the DSM-IV-TR criteria for unipolar MDD, with a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥26, presenting with two or three protocol-defined manic symptoms, who were randomized to 6 weeks of double-blind treatment with either lurasidone 20-60 mg/day (n=109) or placebo (n=100)...
March 30, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28347261/dopamine-d4-receptor-stimulation-contributes-to-novel-object-recognition-relevance-to-cognitive-impairment-in-schizophrenia
#10
Masanori Miyauchi, Nichole M Neugebauer, Herbert Y Meltzer
Several atypical antipsychotic drugs (APDs) have high affinity for the dopamine (DA) D4 receptor, but the relevance to the efficacy for the treatment of cognitive impairment associated with schizophrenia (CIAS) is poorly understood. The aim of this study was to investigate the effects of D4 receptor stimulation or blockade on novel object recognition (NOR) in normal rats and on the sub-chronic phencyclidine (PCP)-induced novel object recognition deficit. The effect of the D4 agonist, PD168077, and the D4 antagonist, L-745,870, were studied alone, and in combination with clozapine and lurasidone...
April 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28344764/atypical-antipsychotics-recent-research-findings-and-applications-to-clinical-practice-proceedings-of-a-symposium-presented-at-the-29th-annual-european-college-of-neuropsychopharmacology-congress-19-september-2016-vienna-austria
#11
REVIEW
Robin Murray, Christoph U Correll, Gavin P Reynolds, David Taylor
Available evidence suggests that second-generation atypical antipsychotics are broadly similar to first-generation agents in terms of their efficacy, but may have a more favourable tolerability profile, primarily by being less likely to cause extrapyramidal symptoms. However, atypical antipsychotics are variably associated with disturbances in the cardiometabolic arena, including increased body weight and the development of metabolic syndrome, which may reflect differences in their receptor binding profiles...
March 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28300012/lurasidone-for-major-depressive-disorder-with-mixed-features-and-irritability-a-post-hoc-analysis
#12
Alan C Swann, Maurizio Fava, Joyce Tsai, Yongcai Mao, Andrei Pikalov, Antony Loebel
OBJECTIVE: The aim of this post-hoc analysis was to evaluate the efficacy of lurasidone in treating major depressive disorder (MDD) with mixed features including irritability. METHODS: The data in this analysis were derived from a study of patients meeting DSM-IV-TR criteria for unipolar MDD, with a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥26, presenting with two or three protocol-defined manic symptoms, and who were randomized to 6 weeks of double-blind treatment with either lurasidone 20-60 mg/d (n=109) or placebo (n=100)...
March 16, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28264739/remission-and-recovery-associated-with-lurasidone-in-the-treatment-of-major-depressive-disorder-with-subthreshold-hypomanic-symptoms-mixed-features-post-hoc-analysis-of-a-randomized-placebo-controlled-study-with-longer-term-extension
#13
Joseph F Goldberg, Daisy Ng-Mak, Cynthia Siu, Chien-Chia Chuang, Krithika Rajagopalan, Antony Loebel
OBJECTIVE: This post-hoc analysis assessed rates of symptomatic and functional remission, as well as recovery (combination of symptomatic and functional remission), in patients treated with lurasidone for major depressive disorder (MDD) associated with subthreshold hypomanic symptoms (mixed features). METHOD: Patients with MDD plus two or three manic symptoms (defined as per the DSM-5 mixed-features specifier) were randomly assigned to flexible-dose lurasidone 20-60 mg/day (n=109) or placebo (n=100) for 6 weeks, followed by a 3-month open-label, flexible-dose extension study for U...
March 7, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28264635/lurasidone-compared-to-other-atypical-antipsychotic-monotherapies-for-bipolar-depression-a-systematic-review-and-network-meta-analysis
#14
Michael Ostacher, Daisy Ng-Mak, Pankaj Patel, Dionysios Ntais, Max Schlueter, Antony Loebel
OBJECTIVES: To assess the efficacy and tolerability of lurasidone versus other atypical antipsychotic monotherapy agents in patients with bipolar depression, using a Bayesian network meta-analysis. METHODS: Fourteen randomised clinical trials (6221 patients) of lurasidone, quetiapine (extended release and immediate release), aripiprazole, olanzapine, and ziprasidone for bipolar depression were included. Efficacy assessments included change in the Montgomery-Åsberg Depression Rating Scale (MADRS), rates of response (≥50% improvement in MADRS) and remission (MADRS ≤12 at study endpoint), and change in the Clinical Global Impressions-Bipolar Disorder-Severity (CGI-BP-S) scale...
March 7, 2017: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/28255439/case-report-of-a-switch-to-mania-induced-by-lurasidone
#15
Mark Kanzawa, Olga Hadden
No abstract text is available yet for this article.
February 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28225748/case-series-reports-on-lurasidone-associated-mania
#16
Louis A Doan, Steven R Williams, Alexandra Takayesu, Brett Lu
No abstract text is available yet for this article.
April 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28185899/lurasidone-versus-treatment-as-usual-for-cognitive-impairment-in-euthymic-patients-with-bipolar-i-disorder-a-randomised-open-label-pilot-study
#17
Lakshmi N Yatham, Sylvia Mackala, Jayasree Basivireddy, Sharon Ahn, Nazlin Walji, Chen Hu, Raymond W Lam, Ivan J Torres
BACKGROUND: Cognitive impairment is present in euthymic patients with bipolar disorder and correlates with impairments in everyday functioning. We aimed to examine the efficacy of lurasidone adjunctive therapy compared with treatment as usual (TAU) in improving cognition. METHODS: For this randomised, open-label, pilot study, we recruited patients aged 19-65 years with euthymic bipolar I disorder from the Mood Disorder Centre in UBC Hospital (Vancouver, Canada)...
March 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28168632/long-term-use-of-lurasidone-in-patients-with-bipolar-disorder-safety-and-effectiveness-over-2%C3%A2-years-of-treatment
#18
Andrei Pikalov, Joyce Tsai, Yongcai Mao, Robert Silva, Josephine Cucchiaro, Antony Loebel
BACKGROUND: Bipolar disorder is a chronic illness with a 2-year recurrence rate of approximately 50% among individuals receiving treatment in the community. The aim of this 18-month, open-label, continuation study was to evaluate the long-term safety and effectiveness of lurasidone in patients who initially presented with a major depressive episode associated with bipolar disorder, and who had completed at least 6 months of initial treatment with lurasidone. METHODS: Patients with bipolar I depression were enrolled in one of three 6-week, double-blind, placebo-controlled trials (monotherapy with lurasidone, 1 study; adjunctive therapy with lurasidone; and lithium or valproate, 2 studies)...
December 2017: International Journal of Bipolar Disorders
https://www.readbyqxmd.com/read/28141623/activating-and-sedating-adverse-effects-of-second-generation-antipsychotics-in-the-treatment-of-schizophrenia-and-major-depressive-disorder-absolute-risk-increase-and-number-needed-to-harm
#19
Leslie Citrome
PURPOSE/BACKGROUND: Activating and sedating adverse effects of antipsychotics can be obstacles to their use. METHODS/PROCEDURES: This study quantified the activating and sedating properties of first-line oral second-generation antipsychotics by examining the rates of adverse reactions as reported in product labeling for the indications of schizophrenia and adjunctive treatment of major depressive disorder. Additional data sources included regulatory documents, study synopses, and published study reports...
April 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28129315/lurasidone-and-mood-stabilizers-in-treatment-resistant-unipolar-depression-a-case-report-study
#20
Nicolas A Nuñez, Gabriella Gobbi
No abstract text is available yet for this article.
January 26, 2017: Journal of Clinical Psychopharmacology
keyword
keyword
27111
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"